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tively. ConClusions: Hospitalizations for patients with HF are costly. On average 
hospitalizations due to worsening HF could range from $23,800 to $48,500 depending 
on the type of coverage. The costs of hospitalizations were higher in patients with 
commercial insurance when compared to Medicare advantage patients.
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objeCtives: To estimate annual hospitalization rate and associated direct costs 
for Medicare beneficiaries with heart failure (HF). Methods: A 5% (n=3,493,434) 
national sample of Medicare beneficiaries was used to identify individuals with 
first observed primary inpatient claim for HF (ICD-9: 428.xx) between 07/01/2005 
and 12/31/2011. Patients having HF diagnoses in the 6 months prior to first observed 
claim were excluded. Patient demographics, use of HF medications and medical 
devices were reported. Annual hospitalization rate and associated total costs (the 
Centers for Medicare and Medicaid Services payment, as well as patient out-of-
pocket costs) were calculated. In order to account for varying lengths of follow-up, 
a per patient-year estimation method was used to calculate the cumulative rate 
of hospitalizations. Cumulative hospitalization rates and associated costs were 
estimated for all-cause hospitalizations, cardiovascular (CV) hospitalizations and 
HF-related hospitalizations. Results: A total of 63,678 patients met the study cri-
teria. Mean age was 82 years and 61% of patients were women. Among patients 
with part D coverage (n=35,788), 64.6% of patients used β blockers. On average, 
patients were hospitalized 2.19 times per patient-year for all-cause. Patients were 
hospitalized on average 1.02 times per patient-year for HF- and 1.30 times per 
patient-year for CV-related hospitalization. The costs associated with first observed 
all-cause hospitalization were $14,500, for CV-related hospitalization was $17,300 
and for HF-related hospitalization were approximately $16,000. ConClusions: 
CONCLUSIONS: Patients with HF who have been hospitalized had frequent subse-
quent hospitalizations. On an average, these individuals experienced 2 all-cause 
hospitalizations per year, one of them being due to worsening of HF. These hos-
pitalizations were costly, with costs ranging from $14,000 to $17,300 per episode.
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objeCtives: To identify baseline demographics and clinical characteristics asso-
ciated with healthcare costs among patients with atherosclerotic cardiovascular 
disease (ASCVD). Methods: This retrospective cohort study identified newly 
diagnosed ASCVD patients aged ≥ 18 years using claims data from the HealthCore 
Integrated Research Database (HIRDSM) between 1/1/07 and 11/30/12 (index 
date= first ASCVD diagnosis date). Patients had both ≥ 12 month pre- and post-
index insurance enrollment, valid baseline lipid panel values, and no baseline lipid 
lowering medication use. Costs were adjusted to 2013 U.S. dollar values. Bivariate 
analyses and generalized linear models with gamma distribution and log link were 
used to examine baseline factors associated with 12 month follow-up all-cause and 
ASCVD-related healthcare costs. Results: In the regression model for all-cause 
healthcare costs (N= 26,388), older age, plan region including South and West (vs. 
Midwest), higher Quan-Charlson Comorbidity Index, index acute coronary syndrome 
(ACS), ischemic stroke or transient ischemic attack, baseline depression, pain, obe-
sity, and chronic kidney disease, baseline use of antihypertensive agents, antidia-
betic medications, and digoxin, and higher baseline all-cause healthcare costs were 
positively associated with follow-up all-cause healthcare costs (p< 0.05). In addi-
tion, female, Northeast plan (vs. Midwest), Health Maintenance Organization (vs. 
Preferred Provider Organization), Medicare Advantage plans, index coronary heart 
disease (except for ACS) or peripheral artery disease, baseline dyslipidemia, and 
baseline goal attainment of low-density lipoprotein cholesterol (< 100 mg/dL), high-
density lipoprotein cholesterol ( > 40/50 mg/dL for males and females respectively), 
triglycerides (< 150 mg/dL), and total cholesterol level (< 200 mg/dL) were negatively 
associated with follow-up all-cause healthcare costs (p< 0.05). Similar findings 
were reported for ASCVD-related healthcare costs (N= 26,376). ConClusions: As 
expected, age, gender, baseline comorbid conditions, baseline use of specific medi-
cations, baseline lipid profiles, and more severe index ASCVD were significantly 
associated with all-cause and ASCVD-related healthcare costs. Geographic location 
and health insurance type also played a significant role in healthcare costs among 
ASCVD patients.
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objeCtives: To estimate the cumulative annual hospitalization rate for patients 
with heart failure (HF). Methods: A retrospective analysis was undertaken using a 
large US claims database, the Optum Research Database. A per patient-year estima-
tion method was used to calculate a cumulative rate of hospitalization to account for 
varying lengths of follow-up. Patients ≥ 18 years, with a first observed inpatient heart 
failure claim (ICD-9: 428.xx; in primary position) between 01/01/08 and 06/30/13 were 
included. Patients having an inpatient claim for HF in the 2 months prior to the first 
tatin and simvastatin in early 2006, respectively, created a unique opportunity to 
examine how patient cost-sharing differentials for brand-name and generic drugs 
impact therapeutic substitution and medication adherence with statins. Methods: 
Using the 2006 5% Medicare files we identified continuous fee-for-service Part D 
covered patients with hyperlipidemia (ICD-9-CM 272.0-272.4) using the brand-
name statins (atorvastatin or rosuvastatin) between 1/1/2006 and 3/31/2006. The 
quasi-experimental study examined changes in outcomes across the pre- (prior to 
coverage gap) and post- (during coverage gap) periods for non-low income subsidy 
(non-LIS) patients with generic-only coverage in gap who faced substantial increases 
in brand-name statin cost sharing ($28 to $82 per 30-day supply) but no changes in 
generic cost-sharing from the pre- to post-period compared to a control group of 
LIS patients who faced no changes in brand-name ($3) or generic ($1) cost-sharing 
in the pre- and post-periods. The two groups were propensity-score matched on 
sociodemographics and clinical characteristics. Difference-in-difference regressions 
were used to examine impact on use of brand-name statins, generic statins, and 
overall any statin use. In addition, overall adherence (PDC> 0.80) to and discontinua-
tion (30-day gap) of statins was also examined. Results: Compared to LIS patients, 
non-LIS patients had a larger decline in brand-name statin use (-0.24 30-day-sup-
ply/month, p< 0.001), smaller increase in generic statin use (+0.06 30-day-supply/
month, p< 0.001), and hence, an overall drop in any statin use (-0.18 30-day-supply/
month, p< 0.001). Correspondingly, a decrease in adherence (OR: 0.81,p< 0.001) and 
increase in discontinuation (OR: 1.62,p< 0.001) on any statins was observed in non-
LIS patients relative to LIS patients. ConClusions: A substantial brand/generic 
cost-sharing differential was associated with therapeutic substitution of brand-
name statins with generic statins; however, it also resulted in declines in adherence 
and increases in discontinuation of statins.
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objeCtives: Intracoronary atherothrombosis complicates percutaneous coronary 
intervention (PCI). Cangrelor, a novel, intravenous P2Y12 inhibitor reduced the risk 
of death, MI, ischemia-driven revascularization and stent thrombosis at 48 hours 
by 22% compared to clopidogrel in the CHAMPION PHOENIX Trial. An economic 
sub-study was designed, from the perspective of the US healthcare system, to 
determine the direct medical costs during index hospitalization among cangrelor 
vs. clopidogrel patients and the subgroup receiving bivalirudin as antithrombin 
therapy. Methods: Hospital bills were collected from participating US sites in the 
CHAMPION PHOENIX trial. Hospital costs were determined by multiplying itemized 
hospital charges and the cost-center specific cost-to-charge ratios obtained from 
hospital’s Medicare Cost Report (MCR). A model predicting in-hospital costs was 
developed by utilizing multivariate imputation by chained equations (MICE) meth-
odology. The costs were imputed for patients where clinical but not economic data 
were available. After imputation, the index hospital costs from entire US population 
were compared between treatment groups. Results: Thirty-eight US sites were 
invited and 22 participated. One site was excluded due to incomplete MCR. Hospital 
bills from 1117 patients (27.3% of 4,097 CHAMPION PHOENIX US population) were 
utilized. Patients’ baseline characteristics and complications were similar to the 
rest of US population. After the MICE imputation, the index hospitalization costs of 
patients receiving cangrelor and clopidogrel were not statistically different ($11,755 
cangrelor vs. $11,914 clopidogrel, P= NS, difference= $159) even when bivalirudin as 
the anticoagulant was utilized ($12,941 cangrelor/bivalirudin vs. $13,216 clopidogrel/
bivalirudin, P= NS, difference= $275). Data also shows a numerical saving of $109 
for catheterization laboratory costs among cangrelor-treated patients ($9,030 vs. 
$9,139, P= NS) with similar results among bivalirudin subgroup. ConClusions: This 
analysis reveals similar direct medical costs, from the perspective of the US health-
care system, for cangrelor patients (with or without bivalirudin) during the index 
hospitalization and catheterization laboratory in the CHAMPION PHOENIX trial.
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objeCtives: To estimate the mean cost per episode of hospitalization for patients 
with heart failure (HF). Methods: A retrospective analysis was undertaken using a 
large US claims database, the Optum Research Database. Adult patients with a first 
observed inpatient HF claim (ICD-9: 428.xx; in primary position) between 01/01/08 and 
06/30/13 were included. Patients having an inpatient claim for HF in the 2 months 
prior to the first observed claim were excluded. Direct costs included the amount 
paid by insurance plan, co-ordination of benefits and patient out-of-pocket costs. 
Cumulative hospitalization rates were estimated for all HF-related hospitaliza-
tions, cardiovascular (CV) hospitalizations and all-cause hospitalizations, within 
the study period. Results were further categorized by types of insurance, specifi-
cally, commercial and Medicare advantage. Results: A total of 85,938 patients met 
the study criteria of which 68.3% (n= 58,732) had Medicare Advantage coverage and 
31.7% (n= 27,206) had commercial insurance. The mean age was 63 years for patients 
with commercial insurance and 77 years for those with Medicare advantage. For 
the total population (commercial + Medicare advantage), the mean direct costs 
were approximately $30,900 for a HF- related hospitalization, $30,400 for CV-related 
hospitalization, and $25,400 for an all-cause hospitalization. For patients with com-
mercial insurance, the mean costs were approximately $48,500, $47,700 and, $40,000 
for a HF-related, CV-related, and all-cause hospitalization episode, respectively. For 
patients with Medicare advantage, the mean costs were approximately $23,800, 
$23,400 and $19,600 for HF-related, CV-related, and all-cause hospitalizations, respec-
